Search results
Showing 61 to 75 of 214 results for arthritis
Evidence-based recommendations on secukinumab (Cosentyx) for treating active ankylosing spondylitis that has not responded well enough to conventional therapy.
This quality standard covers prevention of falls and assessment after a fall in people who are living in the community, in a residential care setting or staying in hospital and are:
View quality statements for QS86Show all sections
Sections for QS86
- Quality statements
- Quality statement 1: Asking people about falls
- Quality statement 2: Comprehensive falls assessment
- Quality statement 3: Interventions to reduce the risk of falls
- Quality statement 4: Checks for injury after an inpatient fall
- Quality statement 5: Safe manual handling after an inpatient fall
- Quality statement 6: Medical examination after an inpatient fall
- Quality statement 7: Multifactorial risk assessment for older people presenting for medical attention
Secukinumab for treating moderate to severe plaque psoriasis (TA350)
Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.
Summary of the evidence on rituximab (MabThera) for treating skin involvement in systemic sclerosis to inform local NHS planning and decision-making
Cellulitis and erysipelas: antimicrobial prescribing (NG141)
This guideline sets out an antimicrobial prescribing strategy for adults, young people, children and babies aged 72 hours and over with cellulitis and erysipelas. It aims to optimise antibiotic use and reduce antibiotic resistance.
people with persistent peripheral spondyloarthritis (excluding psoriatic arthritis) or undifferentiated spondyloarthritis? Any...
Evidence on the safety and efficacy of midcarpal hemiarthroplasty for wrist arthritis is inadequate in quantity and quality. Therefore,...
This indicator covers the practice can produce a register of people with moderate to severe frailty. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM185
therapeutic monitoring of TNF‑alpha inhibitors in people with rheumatoid arthritis. Any explanatory notes(if applicable) Source guidance
Fever in under 5s: assessment and initial management (NG143)
This guideline covers the assessment and early management of fever with no obvious cause in children aged under 5. It aims to improve clinical assessment and help healthcare professionals diagnose serious illness among young children who present with fever in primary and secondary care.
monitoring of tumour necrosis factor (TNF)‑alpha inhibitors in rheumatoid arthritis Any explanatory notes(if applicable) Source guidance...
within registries of patients receiving biological treatments for psoriatic arthritis to obtain information on long-term outcomes,...
distal radioulnar joint replacement for symptomatic joint instability or arthritis should provide information on patient selection, and...
In development Reference number: GID-TA11733 Expected publication date: 26 August 2026
non-steroidal antiinflammatory drugs (NSAIDs) in adults with rheumatoid arthritis (RA) whose pain or stiffness control is not adequate?...